Breast cancer screening: The evolving evidence

ONCOLOGY (United States)

Volumn 26, Issue 5, 2012, Pages

  Smith, Robert A ^a   Duffy, Stephen W ^b   Tabár, László ^c  

^a AMERICAN CANCER SOCIETY   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c FALUN HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; BREAST SELF EXAMINATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SIZE; CANCER STAGING; CLINICAL PROTOCOL; COMPUTER ASSISTED DIAGNOSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; EARLY DIAGNOSIS; EARLY INTERVENTION; ECHOMAMMOGRAPHY; EVIDENCE BASED MEDICINE; FALSE POSITIVE RESULT; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; IMAGE QUALITY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PATIENT COUNSELING; PHYSICAL EXAMINATION; POPULATION RESEARCH; PRACTICE GUIDELINE; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 84874613138     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
3. Tabár L, Vitak B, Chen HH, et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am. 2000;38:625-51.
4. Howlander N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011.
5. Shapiro S, Strax P, Venet L. Periodic breast cancer screening in reducing mortality from breast cancer. JAMA. 1971;215:1777-85.
6. Tabár L, Fagerberg CJ, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985;1:829-32.
7. Moss SM, Cuckle H, Evans A, et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years follow-up: a randomised controlled trial. Lancet. 2006;368:2053-60.
8. Smith RA, Duffy SW, Gabe R, et al. The randomized trials of breast cancer screening: what have we learned? Radiol Clin North Am. 2004;42:793-806.
9. Tabár L, Vitak B, Chen TH, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011; 260:658-63.
10. US Food and Drug Administration: MQSA National Statistics. 2012. Available at http://www.fda.gov/Radiation-EmittingProducts/ MammographyQualityStandardsActandProgram/FacilityScorecard/ucm113858.htm. Accessed April 17, 2012.
11. Yaffe MJ, Mainprize JG. Risk of radiation-induced breast cancer from mammographic screening. Radiology. 2011;258:98-105.
12. Monsees BS. The Mammography Quality Standards Act. An overview of the regulations and guidance. Radiol Clin North Am. 2000;38:759-72.
13. Kerlikowske K. Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. J Natl Cancer Inst Monogr. 1997;22:79-86.
14. National Cancer Institute Breast Cancer Surveillance Consortium: Performance measures for 1,960,150 screening mammography examinations from 2002 to 2006 by age--based on BCSC data as of 2009. National Cancer Institute, 2012. Available at http://breastscreening.cancer.gov/data/performance/screening/2009/perf_age.html. Accessed on April 17, 2012.
15. National Cancer Institute: Smoothed plots of frequency distributions of PPV3 for 32,031 screening mammography examinations: abnormal results for which biopsy was recommended and performed (among radiologists with 30 or more biopsies performed), 19962005. National Cancer Institute, 2012. Available at http://www.science.gov/topicpages/d/distribution+des+biopsies.html. Accessed April 17, 2012.
16. Yaffe MJ, Mainprize JG, Jong RA. Technical developments in mammography. Health Phys. 2008;95:599-611.
17. Gabe R, Duffy SW. Evaluation of service screening mammography in practice: the impact on breast cancer mortality. Ann Oncol. 2005;16(Suppl 2):ii153-62.
18. Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ. 2011;343:d4411.
19. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med. 2010;363:1203-10.
20. Wu JC, Anttila A, Yen AM, et al. Evaluation of breast cancer service screening programme with a Bayesian approach: mortality analysis in a Finnish region. Breast Cancer Res Treat. 2010;121:671-8.
21. Paap E, Holland R, den Heeten GJ, et al. A remarkable reduction of breast cancer deaths in screened versus unscreened women: a case-referent study. Cancer Causes Control. 2010;21:1569-73.
22. Swedish Organized Service Screening Evaluation Group. Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev. 2006;15:45-51.
23. Duffy SW, Tabár L, Olsen AH, et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England. J Med Screen. 2010;17:25-30.
24. Gabe R, Tryggvadottir L, Sigfusson BF, et al. A case-control study to estimate the impact of the Icelandic population-based mammography screening program on breast cancer death. Acta Radiol. 2007;48:948-55.
25. Hellquist BN, Duffy SW, Abdsaleh S, et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort. Cancer. 2011;117:714-22.
26. Swedish Organized Service Screening Evaluation Group. Effect of mammographic service screening on stage at presentation of breast cancers in Sweden. Cancer. 2007;109:2205-12.
27. Beral V, Alexander M, Duffy S, et al. The number of women who would need to be screened regularly by mammography to prevent one death from breast cancer. J Med Screen. 2011;18:210-2.
28. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011:CD001877.
29. Puliti D, Zappa M, Miccinesi G, et al. An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. Eur J Cancer. 2009; 45:3166-71.
30. Duffy SW, Agbaje O, Tabár L, et al. Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res. 2005; 7:258-65.
31. Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ. 2009;339:b2587.
32. Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ. 2004;328:921-4.
33. Moss S. Overdiagnosis and overtreatment of breast cancer: overdiagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res. 2005;7:230-4.
34. Paci E, Miccinesi G, Puliti D, et al. Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy. Breast Cancer Res. 2006;8:R68.
35. Waller M, Moss S, Watson J, Moller H. The effect of mammographic screening and hormone replacement therapy use on breast cancer incidence in England and Wales. Cancer Epidemiol Biomarkers Prev. 2007;16:2257-61.
36. Olsen AH, Agbaje OF, Myles JP, et al. Overdiagnosis, sojourn time, and sensitivity in the Copenhagen mammography screening program. Breast J. 2006;12:338-42.
37. Hofvind S, Thoresen S, Tretli S. The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program. Cancer. 2004;101:1501-7.
38. Hubbard RA, Kerlikowske K, Flowers CI, et al. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 2011; 155:481-92.
39. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003;53:141-69.
40. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:716-26.
41. Meissner HI, Klabunde CN, Han PK, et al. Breast cancer screening beliefs, recommendations and practices: primary care physicians in the United States. Cancer. 2011;117:3101-11.
42. U.S. Preventive Services Task Force. Screening for breast cancer: recommendations and rationale. Ann Intern Med. 2002;137:344-6.
43. Schwartz LM, Woloshin S, Sox HC, et al. US womens attitudes to false positive mammography results and detection of ductal carcinoma in situ: cross sectional survey. BMJ. 2000;320:1635-40.